S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment

Sponsor
SWOG Cancer Research Network
Study ID
NCT00939328
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • bendamustine hydrochloride — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cell-killing substances to them. Giving bendamustine together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of giving bendamustine together with rituximab and to see how well it works in treating patients with B-cell chronic lymphocytic leukemia that has not responded to previous treatment.

Key Dates

Start date
Sep 30, 2009
Status verified
Mar 2015
Primary completion
Sep 30, 2010
Completion
Sep 30, 2010

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Primary Outcome Measure

Response rate (CR, CRi, or PR)

Related Studies